Inclusion Criteria

Criteria:

- No prior bevacizumab

- Histologically or cytologically confirmed invasive breast carcinoma (recurrent or
metastatic disease)

- Measurable disease, defined as >= 1 unidimensionally measurable lesion >= 20 mm by
conventional techniques or >= 10 mm by spiral CT scan

- Patients who may still benefit from hormonal therapy are ineligible (patients with
hormone receptor-positive breast cancer should have received appropriate sequential
hormonal therapy for metastatic disease until disease progression)

- Patients with HER-2 positive disease who have not yet received trastuzumab
(Herceptin®) to maximal benefit are ineligible (patients with disease progression
during trastuzumab therapy are eligible)

- No known brain metastases

- ECOG performance status (PS) 0-1 or Karnofsky PS 60-100%

- Life expectancy > 12 weeks

- Absolute neutrophil count >= 1,500/mm³

- Platelets >=100,000/mm³

- Total bilirubin normal (exception made for patients with known Gilbert's disease)

- AST/ALT =< 2.5 times upper limit of normal (ULN)

- No proteinuria > +1 on two consecutive dipsticks taken >= 1 week apart

- PT/INR/PTT =< 1.2 times ULN

- No allergic reactions attributed to compounds of similar chemical or biologic
composition to pazopanib or other study agents

- No QTc prolongation (defined as a QTc interval >= 500 msecs) or other significant ECG
abnormalities

- No condition (e.g., gastrointestinal tract disease resulting in an inability to take
oral medication or a requirement for IV alimentation, or active peptic ulcer disease)
that would impair ability to swallow and retain study drug

- No poorly controlled hypertension (systolic blood pressure [BP] >= 140 mm Hg or
diastolic BP >= 90 mm Hg) Initiation or adjustment of BP medication is allowed prior
to study entry provided that the average of 3 BP readings prior to study entry is <
140/90 mm Hg

- No serious or non-healing wound, ulcer, or bone fracture

- No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within
the last 4 weeks

- No cerebrovascular accident within the last 6 months

- No myocardial infarction, cardiac arrhythmia, hospital admission for unstable angina
within the last 12 weeks

- No venous thrombosis within the last 12 weeks

- No NYHA class III-IV heart failure Patients with a history of class II heart failure
may be considered eligible provided they are asymptomatic on treatment

- No concurrent uncontrolled illness including, but not limited to, ongoing or active
infection or psychiatric illness/social situations that would preclude study
compliance

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C),
radiotherapy, or surgery

- No cardiac angioplasty or stenting within the last 12 weeks

- No more than 1 prior chemotherapy regimen for recurrent disease

- No prior surgical procedures affecting absorption

- No CYP2C9 substrates during or for 1-2 weeks after completion of study treatment,
including any of the following:

Therapeutic warfarin Low molecular weight heparin or prophylactic low-dose warfarin are
allowed

- No CYP2C9 substrates during or for 1-2 weeks after completion of study treatment,
including any of the following:

- Erectile dysfunction agents: sildenafil, tadalafil, or vardenafil

- Antiarrhythmics: bepridil, flecainide, lidocaine, mexilitine, amiodarone, or
quinidine

- Immune modulators: cyclosporine, tacrolimus, or sirolimus

- Miscellaneous: theophylline, quetiapine, or risperidone

- No CYP2C9 substrates during or for 1-2 weeks after completion of study treatment,
including any of the following:

- Oral hypoglycemics: glipizide, glyburide, or tolbutamide

- Ergot derivatives: dihydroergotamine, ergonovine, ergotamine, or
methylergonovine

- Neuroleptics: pimozide

- No concurrent combination antiretroviral therapy for HIV-positive patients

- No other concurrent investigational agents

- No other concurrent anticancer therapy

- WBC >= 3,000/mm³

- No more than 2 prior palliative systemic chemotherapy regimens for de novo metastatic
disease

- Creatinine normal OR creatinine clearance >= 60 mL/min

- At least 3 months since prior trastuzumab